This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
3 Stocks to Buy for Consistent Dividend Growth
by Ethan Feller
Some of these companies have been around for over 100 years and have seen all imaginable economic environments
Three Reasons to Add BD (BDX) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.
BD (BDX) Boosts Molecular Diagnostics Portfolio With New Tests
by Zacks Equity Research
Recent developments in the Molecular Diagnostics space have been aiding key MedTech players like BD (BDX) to boost their business.
BDX or ALGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BDX vs. ALGN: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Schlumberger, Becton Dickinson, Marathon Petroleum, Twilio and Molson Coors Beverage
by Zacks Equity Research
Schlumberger, Becton Dickinson, Marathon Petroleum, Twilio and Molson Coors Beverage are included in this Analyst Blog.
Veeva Systems (VEEV) Q4 Earnings Beat, Margins Decline
by Zacks Equity Research
Veeva Systems' (VEEV) Q4 results reflect impressive performances by both segments.
Top Analyst Reports for Schlumberger, Becton Dickinson & Marathon Petroleum
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Schlumberger Limited (SLB), Becton, Dickinson and Company (BDX) and Marathon Petroleum Corporation (MPC).
National Vision (EYE) Q4 Revenues Miss Mark, Margins Down
by Zacks Equity Research
National Vision (EYE) is facing a challenging macroeconomic environment, which negatively impacted its performance in the fourth quarter of 2022.
Myriad Genetics (MYGN) Q4 Earnings Top, Gross Margin Falls
by Zacks Equity Research
Myriad Genetics (MYGN) hereditary cancer testing volume registered strong growth in the fourth quarter. GeneSight comes up with yet another strong performance.
Masimo (MASI) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q4 sales.
BD's (BDX) New FDA Approval to Improve Cervical Cancer Testing
by Zacks Equity Research
BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of cervical cancer.
Insulet (PODD) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Insulet's (PODD) Q4 performance benefits from record quarterly U.S. and Total Omnipod new customer starts.
Inogen (INGN) Q4 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
Inogen's (INGN) fourth-quarter results benefit from higher revenues in its domestic business-to-business sales channel.
OPKO Health (OPK) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.
DaVita (DVA) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Despite DaVita's (DVA) robust revenues in its Other segment, its overall Q4 performance was soft.
Merit Medical (MMSI) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in its Cardiovascular segment and the majority of product categories within its Cardiovascular unit.
Avanos (AVNS) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Avanos' (AVNS) fourth-quarter 2022 results reflect strength in both segments.
BD's (BDX) Latest Combination Test Receives the FDA's EUA
by Zacks Equity Research
BD's (BDX) new combination test is likely to significantly aid clinicians in treating patients in the current and future respiratory virus seasons.
BDX vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
BDX vs. WST: Which Stock Is the Better Value Option?
BD (BDX) Q1 Earnings and Revenues Beat Estimates, Margins Down
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.
Becton Dickinson (BDX) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.61% and 0.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Earnings to Watch on Feb 2: BDX, DGX & CNMD
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how BDX, DGX and CNMD are likely to fare this time.
Should You Buy Becton Dickinson (BDX) Ahead of Earnings?
by Zacks Equity Research
Becton Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have driven up Q1 sales.
Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) second-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.